Stock Events

Stock Events

Shattuck Labs 

€5.14
0
+€0.04+0.78% 07:03 Today

Statistics

Day High
5.14
Day Low
5.14
52W High
5.14
52W Low
4.73
Volume
-
Avg. Volume
-
Mkt Cap
515.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q2 2026
Next
-0.11
-0.1
-0.1
-0.09
Expected EPS
-0.09456442949999999
Actual EPS
N/A

Financials

-4,992.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
851,950Revenue
-42.53MNet Income

Analyst Ratings

$11.95Average Price Target
The highest estimate is ⁦14.42⁩.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 82S.F. It's not an investment recommendation.
Amazon
3
AMZN
Tesla
3
TSLA
Carnival
3
CCL
Chewy
3
CHWY

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotech that competes with Shattuck Labs' focus on developing innovative immunotherapies.
Intellia Therapeutics
NTLA
Mkt Cap1.72B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, directly competing with Shattuck Labs in the field of genomic medicine.
Editas Medicine
EDIT
Mkt Cap402.38M
Editas Medicine operates in the genome editing sector, making it a competitor to Shattuck Labs as both seek to harness advanced technologies for therapeutic development.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, competing with Shattuck Labs in the broader immunotherapy and cell therapy market.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies for cancer, competes with Shattuck Labs in the oncology and immunotherapy space.
Novartis
NVS
Mkt Cap268B
Novartis, through its innovative healthcare solutions including CAR T-cell therapy Kymriah, competes in the same immunotherapy space as Shattuck Labs.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb, with a strong portfolio in immuno-oncology and cellular therapy, is a major competitor to Shattuck Labs in the development of cancer treatments.
Merck
MRK
Mkt Cap356.01B
Merck & Co., known for its blockbuster cancer drug Keytruda, competes with Shattuck Labs in the immunotherapy and oncology market.

About

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Show More
CEO
Taylor H. Schreiber
Employees
40
Country
United States
ISIN
US82024L1035
WKN
000A2QD61

Listings

XNAS
US
STTK
BOATS
BOATS
STTK.BOATS
F
DE
82S.F

0 Comments

Share your thoughts

FAQs

What is Shattuck Labs stock price today?▼
The current price of 82S.F is €5.14 EUR — it has increased by +0.78% in the past 24 hours. Watch Shattuck Labs stock price performance more closely on the chart.
What is Shattuck Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Shattuck Labs stocks are traded under the ticker 82S.F.
What is Shattuck Labs market cap?▼
Today Shattuck Labs has the market capitalization of 515.87M
When is the next Shattuck Labs earnings date?▼
Shattuck Labs is going to release the next earnings report on November 10, 2026.
What were Shattuck Labs earnings last quarter?▼
82S.F earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.11 EUR resulting in a +3.28% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Shattuck Labs revenue for the last year?▼
Shattuck Labs revenue for the last year amounts to 851,950 EUR.
What is Shattuck Labs net income for the last year?▼
82S.F net income for the last year is -42.53M EUR.
How many employees does Shattuck Labs have?▼
As of October 28, 2026, the company has 40 employees.
In which sector is Shattuck Labs located?▼
Shattuck Labs operates in the Health & Wellness sector.
When did Shattuck Labs complete a stock split?▼
The last stock split for Shattuck Labs was on December 6, 2016 with a ratio of 1:800.
Where is Shattuck Labs headquartered?▼
Shattuck Labs is headquartered in AUSTIN, United States.